What was the main objective of the IM-UNITI maintenance study?
A. To investigate the efficacy and safety of Ustekinumab 90 mg q8w or q12w versus placebo over a 44-week period
B. To investigate the efficacy and safety of Ustekinumab 130 mg q5w or q10w versus placebo over a 44-week period
C. To investigate the efficacy and safety of Ustekinumab 80 mg q12w versus adalimumab or placebo over a 44-week period
D. To investigate the efficacy and safety of Ustekinumab ~6 mg/kg or 130 mg versus placebo over a 48-week period
Preview next quiz:
What was the CDAI range of patients with Crohn’s disease in UNITI-1 and UNITI-2?
A. 300–450
B. 220–450
C. 150–350
D. 280–400
Disclaimer:
Medical Quiz should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional. All content on this website is for informational and educational purposes only.